絞り込み

17449

広告

「"Cohen AT "[Author]」の検索結果

254件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.

Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer.

Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care.

Non-cytotoxic Dityrosine Photocrosslinked Polymeric Materials With Targeted Elastic Moduli.

Machine learning to predict venous thrombosis in acutely ill medical patients.

Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients.

Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation.

Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality.

Is there a role for low-dose DOACs as prophylaxis?

Predicting atrial fibrillation in primary care using machine learning.

Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database.

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.

Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.

Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial.

Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります